X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ASC42 is an orally available FXR agonist, small molecule drug candidate, which is currently being evaluated for the treatment of primary biliary cholangitis.
Lead Product(s): ASC42
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC42
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
ASC41, once daily oral tablet is a thyroid hormone receptor β (THRβ) agonist. It is under phase 2 clinical development for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH).
Lead Product(s): ASC41
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC41
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
ASC22 (envafolimab) is the signal transmission to T cells and promotes T cell activation by blocking both PD-1/PD-L1 and PD-L1/cluster of differentiation 80 (CD80) signaling pathways, which is investigated for chronic hepatitis b.
Lead Product(s): Envafolimab
Therapeutic Area: Infections and Infectious Diseases Product Name: ASC22
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Lead Product(s): Denifanstat,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Sagimet Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in Combined with Bevacizumab for Treatment of Recurrent Glioblastoma.
Lead Product(s): ASC40,Bevacizumab
Therapeutic Area: Oncology Product Name: ASC40
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
ASC42 is an in-house developed, novel non-steroidal, selective, potent FXR agonist with best-in-class potential and global intellectual property, which is investigated for the treatment of Primary Biliary Cholangitis.
Lead Product(s): ASC42
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: ASC42
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
ASC10 is an oral prodrug (active metabolite ASC10-A), also known as β-D-N4-hydroxycytidine (NHC) or EIDD-1931. It is a potent inhibitor against respiratory syncytial virus infection and is also being investigated for COVID-19.
Lead Product(s): ASC10
Therapeutic Area: Infections and Infectious Diseases Product Name: ASC10
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Product Name: ASC40
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
ASC22 (envafolimab) shows anti-tumor activity by blocking inhibitory signal transmission to T cells and promotes T cell activation by blocking both PD-1/PD-L1 and PD-L1/cluster of differentiation 80 (CD80) signaling pathways.
Lead Product(s): Envafolimab
Therapeutic Area: Infections and Infectious Diseases Product Name: ASC22
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
